康龍化成(300759.SZ):擬在寧波杭州灣新區建設生物醫藥基地項目
格隆匯 8 月 28日丨康龍化成(300759.SZ)公佈,2020年8月28日下午,公司參與了浙江省寧波杭州灣新區開發建設管理委員會在寧波市舉行的杭州灣新區重點項目集中籤約會見儀式。
公司擬在寧波市杭州灣新區建設生物醫藥基地項目,未來總投資意向約35億元,主要實施生物醫藥的研發、中試和生產服務等。公司將按照“總體規劃、分步實施”的原則,逐步組織落實項目計劃。
上述生物醫藥基地項目屬於計劃性事項,項目投資規模僅為項目規劃所預計的數據,存在投資安排尚未確定,內外部市場環境變化等多種不確定因素的影響,不構成公司對投資者的實質性承諾,敬請投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.